Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1TEGSEDI and WAYLIVRA revenue, net

02 3Tegsedi

03 2Tegsedi and Waylivra Revenue, Net

PharmaCompass

01

Brand Name : Tegsedi

Inotersen

arrow
The Pharmacy Technology
Not Confirmed

Brand Name : Tegsedi

arrow
The Pharmacy Technology
Not Confirmed

Inotersen

Main Therapeutic Indication : Genetic Disorders

Currency : USD

2021 Revenue in Millions : 46

2020 Revenue in Millions : 0

Growth (%) : 100

blank

02

Brand Name : TEGSEDI and WAYLIVRA revenue, net

Inotersen

arrow
The Pharmacy Technology
Not Confirmed

Brand Name : TEGSEDI and WAYLIVRA revenue, net

arrow
The Pharmacy Technology
Not Confirmed

Inotersen

Main Therapeutic Indication : Genetic Disorders

Currency : USD

2021 Revenue in Millions : 56

2020 Revenue in Millions : 70

Growth (%) : -21

blank

03

Brand Name : Tegsedi and Waylivra Revenue, Net

Inotersen

arrow
The Pharmacy Technology
Not Confirmed

Brand Name : Tegsedi and Waylivra Revenue, Net

arrow
The Pharmacy Technology
Not Confirmed

Inotersen

Main Therapeutic Indication : Genetic Diseases

Currency : USD

2022 Revenue in Millions : 30

2021 Revenue in Millions : 56

Growth (%) : -46

blank

04

Brand Name : Tegsedi and Waylivra Revenue, Net

Inotersen

arrow
The Pharmacy Technology
Not Confirmed

Brand Name : Tegsedi and Waylivra Revenue, Net

arrow
The Pharmacy Technology
Not Confirmed

Inotersen

Main Therapeutic Indication : Genetic Diseases

Currency : USD

2023 Revenue in Millions : 35

2022 Revenue in Millions : 30

Growth (%) : 16

blank

05

Brand Name : Tegsedi

Inotersen

arrow
The Pharmacy Technology
Not Confirmed

Brand Name : Tegsedi

arrow
The Pharmacy Technology
Not Confirmed

Inotersen

Main Therapeutic Indication : Genetic Diseases

Currency : USD

2022 Revenue in Millions : 40

2021 Revenue in Millions : 46

Growth (%) : -12

blank

06

Brand Name : Tegsedi

Inotersen

arrow
The Pharmacy Technology
Not Confirmed

Brand Name : Tegsedi

arrow
The Pharmacy Technology
Not Confirmed

Inotersen

Main Therapeutic Indication : Genetic Diseases

Currency : USD

2023 Revenue in Millions : 29

2022 Revenue in Millions : 40

Growth (%) : -29

blank